Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220165 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
A Phase 1 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03220165 is a Phase 1 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT03220165, a Phase 1 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.
Interventions
- DRUG MGL-3196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-08-06 |
| Est. Completion | 2017-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220165
The ClinicalTrials.gov registry entry for NCT03220165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGL-3196 is the first listed.
NCT03220165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03220165 about?
NCT03220165 is a clinical study titled "Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196". The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.
What is the current status of trial NCT03220165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-08-06. Estimated completion is 2017-09-03.
What interventions are being tested in trial NCT03220165?
The interventions under investigation include: MGL-3196 (DRUG).
Who is sponsoring clinical trial NCT03220165?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.